BMS-181885

BMS-181885 is a selective 5-HT1 receptor agonist and a ligand for 5-HT1B/1D receptors. BMS-181885 exhibits anti-migraine activity. BMS-181885 can be used in the research of neurological diseases such as migraine[1][2][3].

165250-47-5

12352005

5-HT Receptor

GPCR/G Protein; Neuronal Signaling

Neurological Disease

O=C1C(C(NC2=CC3=C(NC=C3CCCN4CCN(C5=NC=NC=C5OC)CC4)C=C2)=C1C)=O

C25H28N6O3

460.53

[1]Srinivas NR, et al. Absolute bioavailability and dose proportionality of BMS-181885, an antimigraine agent, following the administration of single intranasal doses to cynomolgus monkeys. J Pharm Sci. 1998 Sep;87 (9) :1170-2.|[2]Schulze G E, et al. Intranasal toxicity of BMS-181885, a novel 5-HT1 agonist. International journal of toxicology, 1999, 18 (5) : 285-296.|[3]Saxena PR, et al. BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol. 1998 Jun 26;351 (3) :329-39.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19238/

Reference compound1

No Development Reported

5-HT1 Receptor